PD-1/PD-L1抑制剂联合奥沙利铂化疗治疗胃癌的效果及预后观察  

Observation of efficacy and prognosis of PD-1/PD-L1 inhibitor combined with oxaliplatin chemotherapy in the treatment of gastric cancer

作　　者：张志红[1] 常样样 周小钿 Zhang Zhihong;Chang Yangyang;Zhou Xiaodian(WardⅡ,Department of Medical Oncology,Pingdingshan First People's Hospital,Pingdingshan 467000,China)

机构地区：[1]平顶山市第一人民医院肿瘤内科二病区,平顶山467000

出　　处：《中国实用医刊》2024年第21期104-107,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨程序性死亡受体-1/程序性死亡配体-1(PD-1/PD-L1)抑制剂联合奥沙利铂化疗对胃癌患者疗效和预后的影响。方法队列研究。抽取2021年1月至2023年1月在平顶山市第一人民医院接受治疗的胃癌患者115例,根据治疗方法分为观察组(59例)和对照组(56例)。观察组给予PD-1/PD-L1抑制剂信迪利单抗联合奥沙利铂,对照组给予单纯奥沙利铂化疗治疗,治疗周期为12周。观察两组疗效、血清学变化、预后情况及不良反应发生率。结果观察组治疗总有效率(81.36%,48/59)高于对照组(58.93%,33/56),P<0.05。治疗后,观察组糖类抗原199、糖类抗原724、癌胚抗原水平均低于对照组(P均<0.05)。观察组无进展生存期[(11.96±3.69)个月]、总生存期[(19.64±5.67)个月]均高于对照组[(8.12±1.54)、(13.47±4.79)个月],P均<0.05。结论相比于单独奥沙利铂化疗,PD-1/PD-L1抑制剂联合奥沙利铂更有利于治疗胃癌,可改善患者血清癌症标志物水平和预后情况,提高患者无进展生存期和总生存期,且药物不良反应发生率低。ObjectiveTo investigate the efficacy and prognosis of programmed cell death receplor-1/programmed death ligand-I(PD-1/PD-L1)inhibitor combined with oxaliplatin chemotherapy in the treatment of gastric cancer.MethodsA total of 115 patients with gastric cancer treated in Pingdingshan First People’s Hospital from January 2021 to January 2023 were selected for the cohort study.And they were divided into an observation group(59 cases)and a control group(56 cases)based on treatment method.The observation group received PD-1/PD-L1 inhibitor(sintilimab)combined with oxaliplatin,while the control group received oxaliplatin chemotherapy alone.The treatment cycle was 12 weeks.The therapeutic effect,serological changes,prognosis,and incidence of adverse reactions during treatment of the two groups were observed.ResultsThe total effective rate in the observation group(81.36%,48/59)was significantly higher than that in the control group(58.93%,33/56),P<0.05.After treatment,the levels of carbohydrate antigen 199,carbohydrate antigen 724,and carcinoembryonic antigen in the observation group were lower than those in the control group(all P<0.05).The progression-free survival time in the observation group was(11.96±3.69)months,and the overall survival time was(19.64±5.67)months,both of which were higher than the(8.12±1.54)months and(13.47±4.79)months in the control group(all P<0.05).ConclusionsCompared with oxaliplatin chemotherapy alone,PD-1/PD-L1 inhibitor combined with oxaliplatin has more benefits for treating gastric cancer.It can improve serological indicators and prognosis,increase progression-free survival and overall survival rates without significantly increase in the incidence of adverse drug reactions.

关 键 词：奥沙利铂 程序性死亡受体-1/程序性死亡配体-1抑制剂 信迪利单抗 胃癌 疗效 预后 

分 类 号：R735.2[医药卫生—肿瘤]